Papers
1
Total Citations
24
H-Index
1
About
Weifeng Xu is a leading surgical researcher whose work focuses on advancing minimally invasive treatments for urological cancers, particularly upper urinary tract urothelial carcinoma (UTUC). His most cited study, a 2022 systematic review and meta-analysis comparing robot-assisted nephroureterectomy (RANU) to laparoscopic nephroureterectomy (LNU), has garnered 24 citations and provides critical clarity on a debated clinical question. By synthesizing comparative evidence, Xu demonstrated that while RANU offers no significant advantage over LNU in oncological outcomes, it may reduce hospital stays and blood loss, helping surgeons weigh high-tech options against practical benefits. This contribution has shaped clinical decision-making in urologic oncology. Beyond this landmark paper, Xu’s research portfolio consistently evaluates the efficacy and safety of robotic versus conventional laparoscopic techniques, making him a key voice in evidence-based surgical innovation. His work not only informs best practices for UTUC management but also underscores the importance of rigorous meta-analyses in guiding technology adoption. For students and researchers, Xu exemplifies how systematic reviews can translate complex surgical data into actionable insights that improve patient care.
Research Focus
Key Achievements
Top Papers
- 1